MARKET

ALKS

ALKS

Alkermes Plc
NASDAQ
52.68
-1.11
-2.05%
Opening 09:34 07/10 EDT
OPEN
53.36
PREV CLOSE
53.78
HIGH
53.38
LOW
52.54
VOLUME
37.62K
TURNOVER
--
52 WEEK HIGH
55.67
52 WEEK LOW
25.17
MARKET CAP
8.78B
P/E (TTM)
58.57
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Immunome (IMNM)
TipRanks · 1d ago
Is Alkermes (ALKS) Fully Priced As Russell 2000 Index Inclusion Draws Fresh Attention?
Simply Wall St · 1d ago
Alkermes (ALKS) Gets a Buy from RBC Capital
TipRanks · 1d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evolus (EOLS), Alkermes (ALKS) and VolitionRX (VNRX)
TipRanks · 1d ago
Alkermes Ends Generic VIVITROL Supply Agreement with Amneal
TipRanks · 2d ago
Alkermes Terminates VIVITROL Authorized Generic Supply Agreement With Amneal Without Penalties
Benzinga · 2d ago
ALKERMES - CO AND AMNEAL RELEASE ALL CLAIMS RELATED TO AGREEMENT - SEC FILING
Reuters · 2d ago
Alkermes EVP, CLO David Joseph Gaffin sells 2,034 shares for $109,882.02
PUBT · 3d ago
More
About ALKS
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.

Webull offers Alkermes Plc stock information, including NASDAQ: ALKS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALKS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALKS stock methods without spending real money on the virtual paper trading platform.